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Dear Editor,
E ndothelial cell density decreases with age and in various ocular conditions, including corneal endotheliitis, 
uveitis, pseudoexfoliation syndrome, and birth injury[1]. The 
reduction of endothelial cell density is exacerbated over time 
after intraocular surgery[1]. Descemet stripping automated 
endothelial keratoplasty (DSAEK) is considered the primary 
procedure for patients with only endothelial dysfunction. 
Compared to penetrating keratoplasty, this selective approach 
has several advantages in terms of more rapid visual 
rehabilitation, less surgically-induced astigmatism, less 
incidence of graft rejection, and preservation of biomechanical 
properties[2].
Pseudophakic cystoid macular edema (PCME) is still 
recognized as one of the most common causes of poor visual 
outcome following uneventful cataract surgery[3]. The incidence of 
clinical PCME following modern cataract surgery is reported 
as 1.17%-4.04%[3]. The great variance of incidence can be 
explained by the presence of diabetes, co-pathologic features, 
and intraoperative complications. The dexamethasone implant 
is considered an effective treatment option for patients with 
Irvine-Gass syndrome, even in cases with a longer edema 
duration and in pretreated or refractory cases[3]. Ozurdex™ 
(Allergan, Inc., Irvine, CA, USA) is a biodegradable sustained-
release intravitreal implant of 0.7 mg dexamethasone in the 
NOVADUR (Allergan, Inc., USA) solid polymer drug delivery 
system[4].
A 68-year-old man with no significant past medical history 
underwent uncomplicated phacoemulsification surgery in the 
left eye with in-the-bag intraocular lens (IOL) implantation. 
One month after surgery his visual acuity (VA) improved to 
20/20 with a clear cornea and no macular optical coherence 
tomography (OCT) alteration. Five months later, he was 
referred to a tertiary eye hospital for metamorphopsia 
and progressive visual impairment. Although the slit-
lamp examination revealed a normal anterior segment, at 
fundus evaluation a yellowish macular reflex was detected. 
Fluorescein angiography (FA) and spectral-domain OCT 
(SD-OCT; Spectralis HRA+OCT, Heidelberg Engineering, 
Heidelberg, Germany) demonstrated a late onset PCME 
(Figure 1). Non-steroidal anti-inflammatory drugs (NSAID) 
treatment with topical bromfenac 0.09% (Yellox, Bausch 
& Lomb, Zug, Swiss) was introduced. Six weeks later, VA 
improved to 20/25 and a complete PCME resolution was 
observed. According to the ‘on-off’ phenomena related to the 
cessation and new resumption of the therapy[3], a recurrent 
PCME was noted one month after the end of NSAID 
treatment. A topical bromfenac 0.009% was reintroduced with 
no reduction in macular thickness. Despite the supplementary 
treatment with topical nepafenac 0.3% (Nevanac®, Alcon 
Laboratories, Inc., Fort Worth, TX, USA) for four weeks, no 
additional benefit was detected and the VA decreased to 20/63 
for concomitant pseudophakic bullous keratopathy (PBK) 
developing. An informed consent for a combined DSAEK and 
intravitreal dexamethasone implant (Ozurdex, Allergan Inc., 
Irvine, CA, USA) was obtained. The treatment was performed 
according to the Italian Bioethical Legislation and followed 
the Declaration of Helsinki. At the preoperative evaluation, a 
normal intraocular pressure (IOP) of 14 mm Hg was detected 
and the in vivo confocal analysis demonstrated an endothelial 
cell count of 615 cells/mm2. Although is not recommended 
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for steroid implant, a peripheral iridectomy (PI) during 
DSAEK was performed in order to avoid a pupillary block. 
Dexamethasone 0.15% and oﬂoxacin 1.5% eye drops were 
topically administered 4 times a day, with a stepwise decrease 
in three weeks during the follow-up.
Postoperatively, VA was 20/40, the graft was clear and in 
situ, and the IOL was central and stable. The PCME was 
completely resolved four weeks after the intravitreal Ozurdex 
implant and VA improved to 20/32 (Figure 2). During the nine-
month follow-up, none adverse event and PCME recurrence 
was reported. No IOP spikes were observed with a transient 
increasing up to 18 mm Hg two months after the steroid 
implantation. At in vivo confocal examination, postoperative 
endothelial cell count was 2085, 1973, 1924, 1879 cells/mm2, 
at 1, 3, 6, and 9mo, respectively.
In most cases PCME spontaneously resolve. Only a small 
percentage reaches a clinical relevance and need therapeutic 
treatments. As Zur and Loewenstein[3] reported, topical 
administration of NSAIDs and steroid has been demonstrated 
as a good strategy in the management of PCME. Although 
injection of periocular corticosteroids or systemic treatment 
are viable options for macular edema refractory to topical 
treatment, intravitreal steroids implants were shown to be the 
highly effective and useful solution. 
Ozurdex® (Allergan, Inc., USA) is a biocompatible sustained-
release intravitreal implant (measures 6 mm in length and 
0.46 mm diameter) of 0.7 mg dexamethasone over up 
6mo. It doesn’t need to be retrieved and can be repeatedly 
administered. The use of Ozurdex® implant for the intravitreal 
treatment of macular edema associated with noninfectious 
posterior uveitis was approved for the first time in 2009[4].
Cataract formation and transient IOP increasing are the 
main ocular side effects reported after intravitreal steroids 
insert[4]. The pathogenic conditions related to steroid-induced 
ocular hypertension is not yet fully understood. A trabecular 
meshwork dysfunction may lead to the outﬂow alteration. The 
Figure 1 Left eye preoperative evaluation of concomitant pseudophakic bullous keratopathy and cystoid macular edema  A: Slit-lamp 
photos of bullous keratopathy due to endothelial injury after cataract surgery; B-D: In vivo confocal micrographs, showing endothelium (B) 
posterior (C) and anterior stroma (D) images [ConfoScan 4, Confocal Microscope (Nidek, Inc., Freemont, CA, USA)]; E: Colour fundus imaging 
reveals a pathological yellowish reﬂex in macular area, corresponding to cystoid macular edema; F: FA at middle frames demonstrated intense 
foveal eakage with cystoid intraretinal exudation and subfoveal neurosensorial detachment reported at combined mid/late FA and SD-OCT (G).
Figure 2 Nine months follow-up of combined Descemet stripping automated endothelial keratoplasty and intravitreal dexamethasone 
implant  A: Both the donor and the host corneas were clear at slit-lamp photograph examination; B: Combined infrared and SD-OCT show the 
complete regression of the intraretinal and subretinal exudation, resulting in a integrity of photoreceptors ellipsoid zone and a good VA.
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increased extracellular deposits, the inhibition of trabecular 
meshwork cell function and cytoskeleton rearrangement play a 
key role in the pathogenic mechanism[5].
The corneal decompensation due to Ozurdex wandering 
into the anterior chamber (AC) represents one of the most 
serious complications after the dexamethasone implant[6-18]. 
The mechanism of endothelial decompensation could be 
related to drug toxicity or direct mechanical trauma by the 
implant[18]. According to all cases reported in literature[6-14], a 
PI, a damaged or absent posterior lens capsule, and previous 
vitrectomy, are the main risk factors for Ozurdex migration 
into the AC. However, the presence of any of those risk, does 
not necessarily mean that passage will occur[6]. 
To promptly manage both corneal and retinal diseases, we 
decided for combined DSAEK and intravitreal dexamethasone 
implant for concomitant PBK and PCME. Previous studies 
reported the presence in the corneal stroma of subepithelial 
fibrosis and keratocytes transdifferentiated into fibroblasts 
or myofibroblast in patients with bullous keratopathy[15-16]. A 
common factor related to the expression of these pathological 
changes was found to be the duration of stromal edema, 
which can lead to the development of Descemet’s folds and 
reduced postoperative VA after DSAEK[17]. Related to these 
pathological structural alterations an early surgical timing must 
be considered.
Furthermore, an early treatment of the PCME in order to 
restore the microstructural level of the photoreceptor inner 
segment-outer segment junction integrity results in a better 
final VA and reduce the progression to chronic recurrent stage 
of the PCME[3]. To the best of our knowledge, none previous 
similar combined procedure was reported in literature. 
Whereas no history of prior vitrectomy and not damaged 
posterior lens capsule with uncomplicated phacoemulsification 
and in-the-bag IOL implantation was reported in the past 
medical history, we decided to perform an reduced size inferior 
PI during the corneal endothelial keratoplasty procedure to 
avoid the pupillary block and to reduce the IOP spike after 
the air bubble injection into the AC. In addition to these early 
postoperative conditions, pre-existing glaucoma and topical 
steroid use are considered the most common causes of elevated 
IOP after DSAEK[18]. In this report, none IOP spikes or the 
Ozurdex wandering into the AC were detected during the 
9-month follow-up[19].
As reported by Pedemonte-Sarrias et al[20], cystoid macular 
edema is the most common posterior segment complication 
after DSAEK alone (7%) and responds to standard therapy for 
pseudophakic syndrome. It appears to be more frequent when 
concurrent with phacoemulsification (21%). The concomitant 
the sustained-released intravitreal dexamethasone implantation 
prevent this possible complication and, in addition, allow for 
the reduction of topical steroid administration in postoperative 
management. 
In our opinion, in selected non-vitrectomized eyes without 
damaged or absent posterior lens capsule, combined DSAEK 
and dexamethasone intravitreal implant could be considered 
an effective treatment option for the management of cataract 
surgery complicated by concomitant PCME and PBK.
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